Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
